Corvus Pharmaceuticals, Inc.

The current price of CRVS is $9.73 — it has decreased by 7.95% since the previous close. Data as of Nov 5, 2026.

CRVS is down 3.57% over the past week, down 9.40% over the past month and up 29.22% over the past year. The price is below its 200-day moving average of $14.41.

Analysts' average 12-month price target for CRVS is $27.00, which implies 177.49% upside from the current price. Individual estimates range from $27.00 to $27.00.

Of the 7 analysts covering Corvus Pharmaceuticals, Inc., 1 rates it a strong buy and 6 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Corvus Pharmaceuticals, Inc. has a market capitalization of $818.5M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Corvus Pharmaceuticals, Inc. posted a loss of $0.19 per share against an estimate of -$0.1591, missing expectations by 19.41%. Upcoming reports are listed in the earnings calendar.

Corvus Pharmaceuticals, Inc. has not paid any dividends over the past year.

Companies most comparable to Corvus Pharmaceuticals, Inc. include Arcus Biosciences, Inc., Nektar Therapeutics, CytomX Therapeutics, Inc., Compugen Ltd. and Innate Pharma S.A.

In the latest trading session CRVS moved between $9.69 and $10.55, a range of 8.84% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Corvus Pharmaceuticals, Inc. shows a strong sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Corvus Pharmaceuticals, Inc. is neutral. Technical ratings are indicators, not investment advice.

Over the past 52 weeks CRVS has traded between $6.39 and $26.95. The current price is 63.90% below its 52-week high.